PF-Atlas › Clinical Trials › NCT07299695

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Intravenous immunoglobulin · Phase 3

Registry ID
NCT07299695
Phase
Phase 3
Status
Recruiting
Drug / intervention
Intravenous immunoglobulin (IVIG)
Sponsor
Argyrios Tzouvelekis
Start
2026-01-25
Enrollment
196
Locations
1

About this trial

Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events. Inflammation and immune system imbalance are thought to play an important role in causing AE-IPF. Early clinical experience suggests that intravenous immunoglobulin (IVIG) can be beneficial for patients suffering from AE-IPF. This clinical trial aims to determine whether adding IVIG to usual treatment can improve outcomes for patients hospitalized with AE-IPF.

View NCT07299695 on ClinicalTrials.gov →

Explore related

All Intravenous immunoglobulin trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07299695 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.